ملخص
Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub-Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.
اللغة الأصلية | English |
---|---|
الصفحات (من إلى) | 1667-1674 |
عدد الصفحات | 8 |
دورية | Current Drug Targets |
مستوى الصوت | 14 |
رقم الإصدار | 14 |
المعرِّفات الرقمية للأشياء | |
حالة النشر | Published - 2013 |
منشور خارجيًا | نعم |
ASJC Scopus subject areas
- ???subjectarea.asjc.1300.1313???
- ???subjectarea.asjc.3000.3004???
- ???subjectarea.asjc.3000.3002???
- ???subjectarea.asjc.1300.1308???